The "GLP Laboratory Compliance Documentation and Recordkeeping" training has been added to ResearchAndMarkets.com's offering.
Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback